Collaboration Agreements (Intella Therapeutics) (Details) - Subsequent Event [Member] $ in Millions	1 Months Ended
Apr. 30, 2016 USD ($) target
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaboration Agreement, Share Purchase Obligation	$ 50.0
Intella Therapeutics [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment made in connection with research and development arrangement	$ 75.0
Collaboration Agreement, Number of Targets Company May Have Rights To \| target	10
Number of Payments the Company made	1
Collaboration Agreement, Extension Period	2 years

Collaboration Agreement, Extension Period Upon The Company Making A One-time Payment.

No definition available.

Name:	regn_CollaborationAgreementExtensionPeriod
Namespace Prefix:	regn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Agreement, Maximum Number of Targets Company May Have Rights To

+ References

No definition available.

+ Details

Name:	regn_CollaborationAgreementNumberofTargetsCompanyHasRightsTo
Namespace Prefix:	regn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The Company's maximum contingent obligation to require shares.

+ References

No definition available.

+ Details

Name:	regn_CollaborationAgreementSharePurchaseObligation
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Payments the Company May Make To Extend Term For Two Years.

+ References

No definition available.

+ Details

Name:	regn_NumberofPaymentstheCompanyMayMake
Namespace Prefix:	regn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_IntellaTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: